The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
Author:
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
http://link.springer.com/article/10.1007/s00262-019-02299-8/fulltext.html
Reference20 articles.
1. Greten TF, Sangro B (2018) Targets for immunotherapy of liver cancer. J Hepatol 68:157–166. https://doi.org/10.1016/j.jhep.2017.09.007
2. El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2
3. Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30351-6
4. Duffy AG, Ulahannan SV, Makorova-Rusher O et al (2017) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66:545–551. https://doi.org/10.1016/j.jhep.2016.10.029
5. El-Khoueiry AB, Melero I, Yau T et al (2018) Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): subanalyses of CheckMate-040. J Clin Oncol 36(suppl 4S–abstract):475
Cited by 90 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Toolkit for mapping the clonal landscape of tumor-infiltrating B cells;Seminars in Immunology;2024-03
2. PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation;Journal of Hepatocellular Carcinoma;2024-01
3. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy;BioScience Trends;2023-12-31
4. Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy;Current Opinion in Organ Transplantation;2023-12-27
5. Thermal ablation of hepatocellular carcinoma;Journal of Medical Imaging and Radiation Oncology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3